Home Carbonyls Acetamide, N-[3-[4-[[4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl]carbonyl]phenoxy]propyl]-

Acetamide, N-[3-[4-[[4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl]carbonyl]phenoxy]propyl]-

CAS No.:
131631-89-5
Catalog Number:
AG000ZJK
Molecular Formula:
C26H31N3O4
Molecular Weight:
449.5420
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%
1 week
United States
$182
- +
10mg
98%
1 week
United States
$223
- +
25mg
98%
1 week
United States
$335
- +
50mg
98%
1 week
United States
$446
- +
100mg
98%
1 week
United States
$723
- +
Product Description
Catalog Number:
AG000ZJK
Chemical Name:
Acetamide, N-[3-[4-[[4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl]carbonyl]phenoxy]propyl]-
CAS Number:
131631-89-5
Molecular Formula:
C26H31N3O4
Molecular Weight:
449.5420
MDL Number:
MFCD00903893
IUPAC Name:
N-[3-[4-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy]propyl]acetamide
InChI:
InChI=1S/C26H31N3O4/c1-19(30)27-15-4-18-33-23-10-7-21(8-11-23)26(32)28-16-13-22(14-17-28)29-24-6-3-2-5-20(24)9-12-25(29)31/h2-3,5-8,10-11,22H,4,9,12-18H2,1H3,(H,27,30)
InChI Key:
KSNUCNRMDYJBKT-UHFFFAOYSA-N
SMILES:
CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2c1cccc2
Properties
Complexity:
683  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
449.231g/mol
Formal Charge:
0
Heavy Atom Count:
33  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
449.551g/mol
Monoisotopic Mass:
449.231g/mol
Rotatable Bond Count:
7  
Topological Polar Surface Area:
79A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.6  
Literature
Title Journal
Mechanism of 1-deamino-arginine vasotocin induced natriuresis in rats. General and comparative endocrinology 20110201
Oral oxytocin antagonists. Journal of medicinal chemistry 20100923
Effects of arginine vasotocin and mesotocin on the activation and development of amiloride-blockable short-circuit current across larval, adult, and cultured larval bullfrog skins. Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology 20100301
Effects of hypertonic stimuli and arginine vasotocin (AVT) on water absorption response in Japanese treefrog, Hyla japonica. General and comparative endocrinology 20080601
Effects of arginine vasotocin and vasopressin receptor antagonists on Na+ and Cl- transport in the isolated skin of two frog species, Hyla japonica and Rana nigromaculata. General and comparative endocrinology 20080515
Oxytocin and vasopressin stimulate anion secretion by human and porcine vas deferens epithelia. Biology of reproduction 20070901
Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway. American journal of physiology. Renal physiology 20070801
Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. European journal of pharmacology 20070702
Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice. European journal of pharmacology 20070322
[Renal action of vasopressin]. Nihon rinsho. Japanese journal of clinical medicine 20060201
Enhanced cardiovascular alteration and Fos expression induced by central salt loading in a conscious rat transgenic for the metallothionein-vasopressin fusion gene. Neuroscience research 20051001
Possible involvement of phosphatidylinositol 3-kinase/Akt signal pathway in vasopressin-induced HSP27 phosphorylation in aortic smooth muscle A10 cells. Archives of biochemistry and biophysics 20050615
The effect of AVP-V receptor stimulation on local GFR in the rat kidney. Acta physiologica Scandinavica 20041001
Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. Molecular pharmacology 20040301
Altered cardiovascular regulation in arginine vasopressin-overexpressing transgenic rat. American journal of physiology. Endocrinology and metabolism 20031201
Facilitative role of endogenous oxytocin in noradrenaline release in the rat supraoptic nucleus. The European journal of neuroscience 20031201
Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clinical science (London, England : 1979) 20030701
Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor. Journal of medicinal chemistry 20020606
N-Methylbenzanilide derivatives as a novel class of selective V(1A) receptor antagonists. Bioorganic & medicinal chemistry letters 20020121
Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Progress in brain research 20020101
Intranephron localization and regulation of the V1a vasopressin receptor during chronic metabolic acidosis and dehydration in rats. Pflugers Archiv : European journal of physiology 20010801
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. British journal of pharmacology 19981201
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 19971001
Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life sciences 19950101
Properties